ZYBERNO
Stock Report
Updated Sep 1, 2026

TELA Bio, Inc. (TELA)

Healthcare • NASDAQ

$0.74

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
22.0/100
POOR BUSINESS
TELA Bio, Inc. (TELA) scores 22/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-42.6%)
Return on Capital (Capital Efficiency):CRITICAL (-247.1%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

TELA Bio, Inc. (TELA) stock report — Zyberno Score 22/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, TELA generated -$30.14M in Owner Earnings. Capital was deployed as follows: $535.00K invested in capital expenditures. Reinvestment rate: 0.7%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.74
Market Cap:$42.37M

Valuation Multiples (2)

P/S Ratio:0.53x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$68.56M

Price Action & Momentum (3)

Momentum Percentile:5 / 100
% of 52-Week High:39.5%
B. Profitability Assessment

Return Metrics (4)

ROA:-60.4%
Reinvestment Rate:0.7%
Fundamental Growth Rate (g):-1.8%

Margin Analysis (3)

Operating Margin Ttm:-42.6%
Net Margin Ttm:-51.5%
Ebitda Margin:-41.8%

TTM Performance (3)

Gross Margin Ttm:67.8%
Operating Margin Ttm:-42.6%
Net Margin Ttm:-51.5%

Yield Metrics (2)

Earnings Yield:-$110.16
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-48.1%
Latest Earnings Filed:2026-08-11

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):17.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:2.99x
Quick Ratio:2.38x
Cash Ratio:1.67x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-4.84x
Times Interest Earned:-4.84

Capital Structure (4)

Working Capital:36,273,000.00
Cash And Cash Equivalents:30,424,000.00
Long Term Debt:$56.08M
Net Debt:$26.19M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $79.91M
Linear Growth: 17.1%
📊 Click to view full TELA Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

Gross profit TTM: $54.19M
Linear Growth: 17.1%
📊 Click to view full TELA Gross Profit analysis & methodology →
-$34.01M

Bottom Line Performance (3)

-$41.18M
Income Before Tax:-$40.91M
Ebitda Ttm:-33,384,000.00

Operating Expenses (5)

Operating Expenses:88,198,000.00
R And D Expense:9,543,000.00
Sga Expense:62,696,000.00
Income Tax Expense:$317.00K
Interest Expense:6,967,000.00

Expense Ratios (3)

R And D To Revenue Percentage:49.5%
Sga To Revenue Percentage:325.0%
Ebitda Margin:-41.8%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$59.74M
Current Assets:$54.49M
Ppe Net:2,048,000.00
Goodwill:0.00
Intangible Assets:$1.17M

Liability Structure (4)

Total Liabilities:75,604,000.00
Current Liabilities:18,218,000.00
Long Term Debt:$56.08M
Short Term Debt:$530.00K

Equity & Capital (3)

Equity:-$15.87M
Retained Earnings:-$421.10M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:9,637,000.00
Inventory:11,059,000.00
Accounts Payable:15,335,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:613,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$29.66M-$30.20M

Investment Activities (2)

Investing Cash Flow:$190.00K
Capital Expenditures Ttm:535,000.00

Financing Activities (3)

Financing Cash Flow:-$298.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$42.42M

Non-Cash Items (1)

Depreciation Amortization Ttm:627,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.77
-$0.77
Earnings Per Share Ttm:-$0.72

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.39
Operating Cash Flow Per Share:-$0.49

Book Value & Capital (2)

Book Value Per Share:-$0.28
Cash Per Share:0.53

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.17x
Working Capital Turnover Ttm:2.20x

Receivables Management (2)

Receivables Turnover Ttm:8.29x
Days Sales Outstanding Ttm:44.02

Inventory Management (2)

Inventory Turnover Ttm:7.23x
Days Inventory Outstanding Ttm:50.51

Payables & Cash Cycle (2)

Days Payable Outstanding:70.05
Cash Conversion Cycle:24.49
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$30.14M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.7%
Fundamental Growth Rate (g):-1.8%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):17.1%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):17.1%
Book Value Growth Rate (Linear):-23.3%
C. Company Profile & Context

Corporate Information (6)

Symbol:TELA
Company Name:TELA Bio, Inc.
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:57.41M
Shares Outstanding Basic:57.41M
Shares Outstanding Diluted:57.41M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 04:47:00 UTC
Data Timestamp:2026-08-20T14:06:29.460760
Scroll to Top